T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	4/30/2003 7:53:05 PM
From: JMarcus	Read Replies (1) of 2243

Rick, it is time for me to make my periodic pitch for AVGN. The stock has been moving up these past few days on higher than normal volume, leading me to believe that the bottom may be behind us. It was great to see the stock close above $3.00 today. Per today's press release, they had $116M in cash as of 3/31/03. That is enough to last 4-5 years at their expected annual burn rate of $25M per year. The company has a cash value is $5.77 per share, so it is selling at just a little more than 1/2 its cash value. In what is becoming a frothy market for microcap biotech stocks with news events, it may only take a little positive news to really make this gene therapy company's stock price take off. Besides news about the ongoing Phase I trials in Hemophilia B patients, news of the filing of an IND for the Parkinson's AAV vector coding for the release of aromatic amino acid decarboxylase could cause excitement. Here's a quote from the 10K re upcoming milestones: <<We intend to submit an investigational new drug (IND) application with the Food and Drug Administration (FDA) for our second lead product candidate for the treatment of Parkinson’s disease later in 2003. Our product candidate for the treatment for hemophilia A, Coagulin-A™, is currently in preclinical development and based on the results of preclinical studies in animals and the results of our clinical trials for hemophilia B, we expect to submit an IND with the FDA for Coagulin-A in 2004.>> I already posted the 10K's description of the Parkinson's program here: Message 18900449 The annual stockholders meeting is coming up on May 22nd. I'll see what more I can find out then. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next